iShares Biotechnology ETF
855 hedge funds and large institutions have $7.1B invested in iShares Biotechnology ETF in 2021 Q3 according to their latest regulatory filings, with 71 funds opening new positions, 241 increasing their positions, 293 reducing their positions, and 64 closing their positions.
11% more first-time investments, than exits
New positions opened: 71 | Existing positions closed: 64
2% more call options, than puts
Call options by funds: $456M | Put options by funds: $447M
1% less funds holding
Funds holding: 863 → 855 (-8)
3.81% less ownership
Funds ownership: 70.77% → 66.96% (-3.8%)
7% less capital invested
Capital invested by funds: $7.66B → $7.1B (-$558M)
18% less repeat investments, than reductions
Existing positions increased: 241 | Existing positions reduced: 293
38% less funds holding in top 10
Funds holding in top 10: 13 → 8 (-5)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Advisers
New York
|
+$67M |
| 2 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$66.3M |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$49.4M |
| 4 |
Goldman Sachs
New York
|
+$46.2M |
| 5 |
JP Morgan Chase
New York
|
+$42M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citigroup
New York
|
-$164M |
| 2 |
E
Ergoteles
New York
|
-$99.3M |
| 3 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
-$87.5M |
| 4 |
Bank of Nova Scotia
Toronto,
Ontario, Canada
|
-$81.2M |
| 5 |
Millennium Management
New York
|
-$65.9M |
IBB Hedge Fund Activity: Q3 2021 in Review
855 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in iShares Biotechnology ETF (IBB) for Q3 2021, worth a combined $7.1B — down 7.3% from $7.66B a quarter earlier.
Buyers outnumbered sellers: 71 funds opened new IBB positions and 64 closed out — a net gain of 7 holders — while 241 added to existing stakes and 293 trimmed.
The largest buyer was Two Sigma Advisers, opening a new position worth an estimated $67M. The largest seller was Citigroup, cutting an estimated $164M.
- 855 institutional investors held iShares Biotechnology ETF (IBB) as of Q3 2021, down from 863 in Q2 2021.
- Funds reported $7.1B of iShares Biotechnology ETF stock for Q3 2021, down 7.3% quarter-over-quarter.
- 71 funds opened new iShares Biotechnology ETF positions in Q3 2021 and 64 closed out, a net change of +7 holders.
- The largest iShares Biotechnology ETF buyer in Q3 2021 was Two Sigma Advisers, an estimated $67M added.
- The largest iShares Biotechnology ETF seller in Q3 2021 was Citigroup, an estimated $164M sold.
Based on aggregated 13F filings for Q3 2021.